PACK YOUR BAGS

While the exceptional work being done by organizations like the Multidisciplinary Association for Psychedelic Studies (MAPS) is bringing psychedelics back into prominent discussion in the biggest way since the ’60s, a recent article in the Journal of Psychopharmacology is helping to alleviate many of the concerns surrounding this work. In a randomized, double-blind, controlled study with healthy participants, James Rucker et al. were able to show that moderate doses of psilocybin (the psychoactive component found in some mushrooms) were well tolerated and didn’t have any short- or long-term negative effects on cognition or emotional processing.